PROCEPT BioRobotics to Report Second Quarter 2022 Financial Results on August 4, 2022

Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced it will release its financial results for the second quarter of 2022 on August 4, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. Investors can listen through a webcast or by registering for a call. PROCEPT focuses on surgical robotics and advanced solutions in urology, particularly for treating benign prostatic hyperplasia (BPH). The company highlights its AquaBeam Robotic System and significant clinical evidence supporting its Aquablation therapy.

Positive

• Company focuses on advanced surgical robotics in urology.
• AquaBeam Robotic System targets benign prostatic hyperplasia, a condition affecting 40 million men in the U.S.
• Strong clinical backing with nine studies and over 100 peer-reviewed publications supporting Aquablation therapy.

Negative

• None.

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. The company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

• Webcast link for interested listeners:
  • https://edge.media-server.com/mmc/p/87bcav5x [edge.media-server.com]
• Dial-in registration for sell-side research analysts:
  • https://register.vevent.com/register/BI70e85eb9b03a42e8831726c78237aea4 [register.vevent.com]

Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Gilmartin Group
Matt Bacso, CFA
Matt.bacso@gilmartinir.com 

FAQ

When will PROCEPT BioRobotics report its financial results for Q2 2022?

PROCEPT BioRobotics will report its financial results for Q2 2022 on August 4, 2022, after market close.

What time is the conference call for PROCEPT BioRobotics' Q2 2022 results?

The conference call will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

How can I listen to the PROCEPT BioRobotics conference call?

Investors can listen to the conference call via a webcast or by registering for a call through the company's investor website.

What is the AquaBeam Robotic System?

The AquaBeam Robotic System is designed for minimally invasive urologic surgery, particularly for treating benign prostatic hyperplasia (BPH).

What is Aquablation therapy?

Aquablation therapy is a treatment developed by PROCEPT that provides effective outcomes for men suffering from lower urinary tract symptoms due to BPH, independent of prostate size.